Evidence map›Paper›PMID 37072468›Full record

ArticleScientific reports2023

Results and lessons learned from the sbv IMPROVER metagenomics diagnostics for inflammatory bowel disease challenge.

Lusine Khachatryan, Yang Xiang, Artem Ivanov, Enrico Glaab, Garrett Graham, Ilaria Granata, Maurizio Giordano, Lucia Maddalena, Marina Piccirillo, Ichcha Manipur and 16 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Lusine KhachatryanPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland. Lusine.Khachatryan@pmi.com.
Yang XiangPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Artem IvanovITMO University, St. Petersburg, Russian Federation.
Enrico GlaabUniversity of Luxembourg, Luxembourg, Luxembourg.
Garrett GrahamGeorgetown University, Washington, DC, USA.
Ilaria GranataConsiglio Nazionale delle Ricerche, Naples, Italy.
Maurizio GiordanoConsiglio Nazionale delle Ricerche, Naples, Italy.
Lucia MaddalenaConsiglio Nazionale delle Ricerche, Naples, Italy.
Marina PiccirilloConsiglio Nazionale delle Ricerche, Naples, Italy.
Ichcha ManipurConsiglio Nazionale delle Ricerche, Naples, Italy.
Giacomo BaruzzoUniversity of Padua, Padua, Italy.
Marco CappellatoUniversity of Padua, Padua, Italy.
Batiste AvotUniversity of Fribourg, Fribourg, Switzerland.
Adrian StanPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
James BatteyPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Giuseppe Lo SassoPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Stephanie BouePMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Nikolai V IvanovPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Manuel C PeitschPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Julia HoengPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Laurent FalquetUniversity of Fribourg, Fribourg, Switzerland.
Barbara Di CamilloUniversity of Padua, Padua, Italy.
Mario R GuarracinoConsiglio Nazionale delle Ricerche, Naples, Italy.
Vladimir UlyantsevITMO University, St. Petersburg, Russian Federation.
Nicolas SierroPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Carine PoussinPMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing body of evidence links gut microbiota changes with inflammatory bowel disease (IBD), raising the potential benefit of exploiting metagenomics data for non-invasive IBD diagnostics. The sbv IMPROVER metagenomics diagnosis for inflammatory bowel disease challenge investigated computational metagenomics methods for discriminating IBD and nonIBD subjects. Participants in this challenge were given independent training and test metagenomics data from IBD and nonIBD subjects, which could be wither either raw read data (sub-challenge 1, SC1) or processed Taxonomy- and Function-based profiles (sub-challenge 2, SC2). A total of 81 anonymized submissions were received between September 2019 and March 2020. Most participants' predictions performed better than random predictions in classifying IBD versus nonIBD, Ulcerative Colitis (UC) versus nonIBD, and Crohn's Disease (CD) versus nonIBD. However, discrimination between UC and CD remains challenging, with the classification quality similar to the set of random predictions. We analyzed the class prediction accuracy, the metagenomics features by the teams, and computational methods used. These results will be openly shared with the scientific community to help advance IBD research and illustrate the application of a range of computational methodologies for effective metagenomic classification.

Indexed as

Colitis, UlcerativeCrohn DiseaseGastrointestinal MicrobiomeInflammatory Bowel DiseasesHumansMetagenomics

Identifiers

PMID37072468
PMCPMC10113391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.